Genzyme

Treating mice in a model of multiple sclerosis with Lemtrada (alemtuzumab) prevented the formation of B-cell aggregates in the animals’ central nervous system and disrupted already existing ones, researchers report. The treatment also reduced disease activity when administered at the peak of disease. The study, “Anti-CD52 antibody treatment depletes B…

#ACTRIMS2018 – Third Course of Lemtrada Improves Relapse, Disability in MS Patients, CARE-MS II Trial Shows The normal treatment regimen with Lemtrada is a series of two treatment courses, with the second infusion course given 12 months after the first. A “selling point” for this disease-modifying therapy (DMT) is…

There ‘s a top 10 list of New Year’s resolutions that are most commonly made and then most commonly broken. Lose weight, get fit, stop smoking (well, never touch hard drugs like tobacco), and spend more time with the family (they have no choice unless they leave…

Happy new year to all. The start of the new year seems like a good time to assess what my journey has been like since my first round of Lemtrada (alemtuzumab) back in December 2016. The road has had bumps and hills and dips. But, overall, Lemtrada has…

Genzyme, a specialty care unit of Sanofi, announced that TV and film actress Madeleine Stowe will host its new online series, “Take Action on MS,” focusing on people living with relapsing multiple sclerosis (MS). Stowe, whose father had MS, works with Genzyme to educate people across the U.S. about daily life with the…

An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease. The Coral Gables MS Exchange event will be held from 10:30 a.m. to 2:15 p.m. on…

Two upcoming, free events for members of the multiple sclerosis community are to be held during the next few weeks at Coral Gables, Florida, and San Antonio, Texas, respectively. Sponsored by the pharmaceutical firm Genzyme, these interactive events will provide opportunities for people with MS and members of the MS community…

Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled “Free Communications” took place. In the first session, several topics related to multiple…

Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). The findings were presented today, October 9, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. Lemtrada® (alemtuzumab), developed by Genzyme, is…

Genzyme recently announced a novel worldwide initiative called vs.MS, whose goal is to increase awareness of the psychical and emotional toll of relapsing multiple sclerosis (RMS) on patients and their caregivers. To enhance the comprehension of the full burden of RMS, Genzyme conducted a large-scale survey of more than 1,500 individuals…

A survey of 97 neurologists conducted in June 2015 revealed specialists within the field of neurology are increasingly avoiding prescribing injectables to patients suffering from multiple sclerosis, as orally-available disease modifying-agents (DMAs) continue to gain in popularity. The survey was conducted and reported by Spherix Global Insights, a newly established business…

The non-profit organization MS News and Views (MSVN) announced that it will host four educational events during the month of August for both patients and other people interested in learning more about multiple sclerosis (MS). The educational events reflect the organization’s ongoing mission, which is to collect, present and…

Genzyme Canada has announced that Health Canada has approved its 14 mg dose of AUBAGIO as an expedited exception benefit product through the federal health regulator’s Non-Insured Health Benefits (NIHB) Program for eligible First Nations people and Inuit as a first-line oral tablet therapy for relapsing remitting multiple sclerosis (RRMS).

The Canadian Drug Expert Committee (CDEC) recently recommended that LEMTRADA (alemtuzumab) be included in provincial and other public drug plans for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was made through Canada’s Common Drug Review (CDR) and announced in a press release by the company that…

UK-based MS Trust has announced the launch of new awards designed to distinguish healthcare professionals that are committed to treating and changing the lives of patients who suffer from multiple sclerosis (MS). The QuDos Awards are currently open for nominations and will feature ten different categories. The QuDoS in MS Awards –…

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized by Genzyme is now financially supported by the state as a first-line oral tablet to treat patients who…

This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of a targeted therapeutic strategy for multiple sclerosis (MS).  The research will utilize Genzyme’s early-stage MS research programs involving neuroprotection…

Genzyme presented new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development program on April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…

British Columbia’s PharmaCare drug program has announced that it will fund AUBAGIO, a therapy developed by Genzyme for the treatment of multiple sclerosis. AUBAGIO (teriflunomide) 14 mg has been officially added to PharmaCare’s provincial formulary as a first-line oral agent for patients suffering from relapsing remitting multiple sclerosis (RRMS). As…

Actress and star of the ABC show “Revenge”, Madeleine Stowe, recently shared her personal story of living in a family with someone who suffers from  multiple sclerosis (MS). Her father lived for many years with the disease. The actress has decided to help not only MS patients but…

Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include Aubagio® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line…

With 100,000 Canadians living with Multiple Sclerosis (MS), and three people newly diagnosed every day, Canada has one of the highest prevalence rates for the disease in the world. Most people are diagnosed with relapsing MS in their twenties and thirties, and MS is the most common neurological disease affecting…

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug for relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…

The Food and Drug Administration (FDA) recently accepted the results from Genzyme’s TOWER and TOPIC  clinical trials, which assessed the safety and efficacy of oral, once-daily Aubagio® (teriflunomide) for Multiple Sclerosis, and will add the positive data to the product’s U.S. label. Genzyme is a leader in the development…

Featureflash / Shutterstock.com Television’s “Queen of Mean,” Revenge‘s Madeleine Stowe, recently opened up about her early memories of her father living with multiple sclerosis (MS), a progressive neurodegenerative disease that, until today, does not have a known cure. However, thanks to the efforts of countless researchers and MS…

Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.

The Scottish Medicines Consortium (SMC)  announced the approval of the drug Lemtrada, produced by Genzyme, for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and active disease defined by clinical or imaging features, within the national health system (NHS) in Scotland. Lemtrada…

Lemtrada, a drug produced by Genzyme for the treatment of adult patients suffering from relapsing remitting multiple sclerosis (RRMS) with active disease, was approved by Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT). “We are pleased by the continued global support for Lemtrada,” said Genzyme…